Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.
Under the agreement, Prometheus will receive an upfront payment of an undisclosed amount and could receive up to $420 million in milestone payments.
The firm said that the new funds will enable it to build on the continued commercial expansion of its first product, PredictSure IBD, in the coming months.
In Nature this week: Integrative Human Microbiome Project researchers investigate host-microbiome relationship in health and disease, and more.
Somalogic will use its SomaScan platform to analyze at least 15,000 clinical samples from Janssen to identify protein biomarkers for various diseases.
Life Genomics will distribute Luxia's 1test1 test in Sweden, Denmark, Finland, Iceland, and Norway. The test leverages sequencing technology to analyze the 16s RNA gene.
In Science this week: global transcriptome analysis of inflammatory bowel disease, and more.
The partners aim to determine whether the microbiome can be used to predict patient responses to certain inflammatory bowel disease therapies.
Inhibiting the associated protein, PAI-1, appeared to ease inflammation and symptoms in a mouse model of inflammatory bowel disease.
Genome- and exome-wide association analysis on inflammatory bowel disease patients with or without thiopurine-induced myelosuppression revealed new and known risk genes.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.